Bleakley Financial Group LLC Grows Position in Cencora, Inc. $COR

Bleakley Financial Group LLC increased its position in shares of Cencora, Inc. (NYSE:COR) by 31.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 28,102 shares of the company’s stock after purchasing an additional 6,755 shares during the period. Bleakley Financial Group LLC’s holdings in Cencora were worth $9,492,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Oakworth Capital Inc. purchased a new position in shares of Cencora during the 4th quarter worth about $26,000. Elyxium Wealth LLC bought a new stake in Cencora during the 4th quarter valued at about $27,000. Archer Investment Corp lifted its holdings in Cencora by 134.3% during the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after buying an additional 47 shares in the last quarter. Optima Capital LLC bought a new stake in Cencora during the 4th quarter valued at about $31,000. Finally, IAG Wealth Partners LLC bought a new stake in Cencora during the 3rd quarter valued at about $30,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Trading Up 0.0%

NYSE:COR opened at $275.01 on Tuesday. Cencora, Inc. has a one year low of $244.82 and a one year high of $377.54. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. The firm has a market cap of $53.51 billion, a P/E ratio of 21.09, a P/E/G ratio of 1.27 and a beta of 0.64. The firm has a 50-day simple moving average of $304.15 and a 200-day simple moving average of $336.24.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business had revenue of $78.36 billion during the quarter, compared to the consensus estimate of $81.09 billion. During the same quarter in the prior year, the firm posted $4.42 EPS. The company’s revenue for the quarter was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities analysts anticipate that Cencora, Inc. will post 17.79 EPS for the current fiscal year.

Cencora announced that its board has approved a stock repurchase plan on Thursday, May 21st that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the company to buy up to 3.9% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 1st. Stockholders of record on Friday, May 15th will be issued a $0.60 dividend. The ex-dividend date is Friday, May 15th. This represents a $2.40 annualized dividend and a dividend yield of 0.9%. Cencora’s payout ratio is currently 18.40%.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on COR shares. Leerink Partners reiterated an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. JPMorgan Chase & Co. lifted their price objective on shares of Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a report on Tuesday, February 10th. UBS Group lifted their price objective on shares of Cencora from $410.00 to $412.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Evercore set a $360.00 price objective on shares of Cencora in a report on Wednesday, April 8th. Finally, William Blair started coverage on shares of Cencora in a report on Tuesday, April 28th. They set a “market perform” rating for the company. Twelve equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Cencora currently has an average rating of “Moderate Buy” and a consensus price target of $380.25.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.